Skip to main content
OpenTrials

Clinical trial condition

Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

Explore clinical trials studying Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8. Study availability and eligibility vary by location and protocol.

19 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 trial results

Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

NCT06203600

Conditions
Adenocarcinoma Of Esophagus, Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, +14 more
Locations
  • Baptist Health Medical Center - Little Rock Little Rock, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
  • Kaiser Permanente-Baldwin Park Baldwin Park, California, United States
View all 374 locations
View Trial Details
Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

NCT05677490

Conditions
Adenocarcinoma Of Esophagus, Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 793 locations
View Trial Details
Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

NCT04460937

Conditions
Adenocarcinoma Of Esophagus, Brain Diseases, Brain Neoplasms, +80 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Northwestern University Chicago, Illinois, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

NCT03641313

Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, +5 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 31 locations
View Trial Details

Related conditions